|Systematic (IUPAC) name|
|Molecular mass||360.4 g/mol|
FUBIMINA (also known as BIM-2201, BZ-2201 and FTHJ) is a synthetic cannabinoid that is the benzimidazole analog of AM-2201 and has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in 2013, alongside MEPIRAPIM.
FUBIMINA acts as a reasonably potent agonist for the CB2 receptor (Ki = 23.45 nM), with 12x selectivity over CB1 (Ki = 296.1 nM), and does not fully substitute for Δ9-THC in rat discrimination studies.
- List of AM cannabinoids
- List of JWH cannabinoids
- "FUBIMINA". Cayman Chemical. Retrieved 22 June 2015.
- Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014). "Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products". Forensic Toxicology 32 (1): 105–115.
- Jenny L Wiley, Julie A Marusich, Timothy W Lefever, Kateland R Antonazzo, Michael T Wallgren, Ricardo A Cortes, Purvi R Patel, Megan Grabenauer, Katherine N Moore, and Brian F Thomas (June 2015). "AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice". Journal of Pharmacology and Experimental Therapeutics.
- Daniel Pagé, Elise Balaux, Luc Boisvert, Ziping Liu, Claire Milburn, Maxime Tremblay, Zhongyong Wei, Simon Woo, Xuehong Luo, Yun-Xing Cheng, Hua Yang, Sanjay Srivastava, Fei Zhou, William Brown, Miroslaw Tomaszewski, Christopher Walpole, Leila Hodzic, Stéphane St-Onge, Claude Godbout, Dominic Salois, Keymal Payza (July 2008). "Novel benzimidazole derivatives as selective CB2 agonists". Bioorganic & Medicinal Chemistry Letters 18 (13): 3695–3700.